Top Markets
Coin of the day
TTY Biopharm Company Limited TTY Biopharm Company Limited

TTY Biopharm Company Limited

4105
Rank in Stocks #12158
TTY Biopharm Company Limited, along with its associated entities, specializes... TTY Biopharm Company Limited, along with its associated entities, specializes in the creation and distribution of pharmaceutical and chemical products across Taiwan and global markets. Its operations are structured into several key divisions: Oncology, Intensive Care, Healthcare, Export & CDMO, and an "Other" Business Unit. For anti-cancer and supportive therapies, the company markets a range of oncology medications under prominent brand names such as Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Episil, Otril, Zobonic, Yondelis, and Pemazyre. Addressing infectious diseases and influenza, TTY Biopharm supplies anti-infection drugs including Brosym, Colimycin, Cubicin, Lipo-AB, Agrippal, Cepiro, Flusine, Maxtam, Metacin, and Flucelvax. Furthermore, the firm offers various healthcare-related pharmaceuticals designed for the digestive system, osteoporosis, and metabolic conditions, marketed under brands like Algitab, Alginos, Alginos Fresh, Bio-Cal Plus, and Sulfin. Beyond pharmaceuticals, the company is also involved in distributing functional foods, conducting international trade (import/export), and engaging in investment ventures. Established in 1960, TTY Biopharm maintains its principal office in Taipei, Taiwan.
Share Price
$2.48
Market Cap
$615.94M
Change (1 day)
0.13%
Change (1 year)
-1.37%
Country
TW
Trade TTY Biopharm Company Limited (4105)

Category

P/B ratio for TTY Biopharm Company Limited (4105)
P/B ratio as of 2026 TTM: 0
According to TTY Biopharm Company Limited latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for TTY Biopharm Company Limited from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors